Shares of Rhythm Pharmaceuticals closed down Tuesday after the biotech's experimental weight-loss drug missed its mark in a yearlong study.

More than two out of every five adults in the U.S. are obese. You may have heard that if you move more, you'll protect yourself from weight gain. But a new study shows exercise isn't the most ...

Novo Nordisk fired a direct shot at Eli Lilly this week, releasing data from an indirect trial comparison that claims its ...

According to the World Obesity Federation, an estimated 1.9 billion people worldwide will be affected by obesity in 2035. Maintaining an ideal weight can be challenging in a world where diets and ...

Can combining two gut hormone pathways unlock better obesity treatments? In the first human trial of dapiglutide, researchers found encouraging metabolic signals but no statistically significant edge ...

A new report has some encouraging news about obesity in America. For the first time in more than a decade, the number of states with high obesity rates has dropped. The new report looked at obesity ...

Pfizer PFE reported fourth-quarter 2025 adjusted earnings per share of 66 cents, which comprehensively beat the Zacks Consensus Estimate of 57 cents per share. Earnings rose 5% year over year.

The premise of the campaign appears to be that although 61 per cent of Australians overweight, 50 per cent of those are in denial over their weight problem. Many who are obese don't acknowledge it.

Novo Nordisk shares fell sharply after the Danish drugmaker said a next-generation obesity treatment failed to beat the weight loss delivered by Eli Lilly's Zepbound in a head-to-head study. Shares in ...

Amgen AMGN reported fourth-quarter 2025 adjusted earnings of $5.29 per share, which beat the Zacks Consensus Estimate of $4.76 per share. Earnings were relatively flat year over year as higher ...